ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Candida Infections Drugs Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-3W13685
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Candida Infections Drugs Market Research Report 2023
BUY CHAPTERS

Global Candida Infections Drugs Market Research Report 2025

Code: QYRE-Auto-3W13685
Report
May 2025
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK
Novartis
Astrazeneca plc
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd.
Merck& Co. Inc
Bristol Myers Squibb Company
Lilly
Amgen Inc

Candida Infections Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Candida Infections Drugs Market

Candida Infections Drugs Market

The global market for Candida Infections Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Candida Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Candida Infections Drugs.
The Candida Infections Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Candida Infections Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Candida Infections Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Candida Infections Drugs Market Report

Report Metric Details
Report Name Candida Infections Drugs Market
CAGR 5%
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Bristol-Myers Squibb Company, Lilly, Amgen Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Candida Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Candida Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Candida Infections Drugs Market report?

Ans: The main players in the Candida Infections Drugs Market are F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Bristol-Myers Squibb Company, Lilly, Amgen Inc

What are the Application segmentation covered in the Candida Infections Drugs Market report?

Ans: The Applications covered in the Candida Infections Drugs Market report are Beriberi, Jock Itch, Vaginal Infection, Other

What are the Type segmentation covered in the Candida Infections Drugs Market report?

Ans: The Types covered in the Candida Infections Drugs Market report are Azole, Nystatin, Other

Recommended Reports

Antifungal Drugs

Infectious Disease Drugs

Women's Health Drugs

1 Candida Infections Drugs Market Overview
1.1 Product Definition
1.2 Candida Infections Drugs by Type
1.2.1 Global Candida Infections Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Azole
1.2.3 Nystatin
1.2.4 Other
1.3 Candida Infections Drugs by Application
1.3.1 Global Candida Infections Drugs Market Value by Application (2024 VS 2031)
1.3.2 Beriberi
1.3.3 Jock Itch
1.3.4 Vaginal Infection
1.3.5 Other
1.4 Global Candida Infections Drugs Market Size Estimates and Forecasts
1.4.1 Global Candida Infections Drugs Revenue 2020-2031
1.4.2 Global Candida Infections Drugs Sales 2020-2031
1.4.3 Global Candida Infections Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Candida Infections Drugs Market Competition by Manufacturers
2.1 Global Candida Infections Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Candida Infections Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Candida Infections Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Candida Infections Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Candida Infections Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Candida Infections Drugs, Product Type & Application
2.7 Global Key Manufacturers of Candida Infections Drugs, Date of Enter into This Industry
2.8 Global Candida Infections Drugs Market Competitive Situation and Trends
2.8.1 Global Candida Infections Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Candida Infections Drugs Players Market Share by Revenue
2.8.3 Global Candida Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Candida Infections Drugs Market Scenario by Region
3.1 Global Candida Infections Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Candida Infections Drugs Sales by Region: 2020-2031
3.2.1 Global Candida Infections Drugs Sales by Region: 2020-2025
3.2.2 Global Candida Infections Drugs Sales by Region: 2026-2031
3.3 Global Candida Infections Drugs Revenue by Region: 2020-2031
3.3.1 Global Candida Infections Drugs Revenue by Region: 2020-2025
3.3.2 Global Candida Infections Drugs Revenue by Region: 2026-2031
3.4 North America Candida Infections Drugs Market Facts & Figures by Country
3.4.1 North America Candida Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Candida Infections Drugs Sales by Country (2020-2031)
3.4.3 North America Candida Infections Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Candida Infections Drugs Market Facts & Figures by Country
3.5.1 Europe Candida Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Candida Infections Drugs Sales by Country (2020-2031)
3.5.3 Europe Candida Infections Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Candida Infections Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Candida Infections Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Candida Infections Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Candida Infections Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Candida Infections Drugs Market Facts & Figures by Country
3.7.1 Latin America Candida Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Candida Infections Drugs Sales by Country (2020-2031)
3.7.3 Latin America Candida Infections Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Candida Infections Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Candida Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Candida Infections Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Candida Infections Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Candida Infections Drugs Sales by Type (2020-2031)
4.1.1 Global Candida Infections Drugs Sales by Type (2020-2025)
4.1.2 Global Candida Infections Drugs Sales by Type (2026-2031)
4.1.3 Global Candida Infections Drugs Sales Market Share by Type (2020-2031)
4.2 Global Candida Infections Drugs Revenue by Type (2020-2031)
4.2.1 Global Candida Infections Drugs Revenue by Type (2020-2025)
4.2.2 Global Candida Infections Drugs Revenue by Type (2026-2031)
4.2.3 Global Candida Infections Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Candida Infections Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Candida Infections Drugs Sales by Application (2020-2031)
5.1.1 Global Candida Infections Drugs Sales by Application (2020-2025)
5.1.2 Global Candida Infections Drugs Sales by Application (2026-2031)
5.1.3 Global Candida Infections Drugs Sales Market Share by Application (2020-2031)
5.2 Global Candida Infections Drugs Revenue by Application (2020-2031)
5.2.1 Global Candida Infections Drugs Revenue by Application (2020-2025)
5.2.2 Global Candida Infections Drugs Revenue by Application (2026-2031)
5.2.3 Global Candida Infections Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Candida Infections Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd
6.1.1 F. Hoffmann-La Roche Ltd Company Information
6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.2 Mylan NV
6.2.1 Mylan NV Company Information
6.2.2 Mylan NV Description and Business Overview
6.2.3 Mylan NV Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Mylan NV Candida Infections Drugs Product Portfolio
6.2.5 Mylan NV Recent Developments/Updates
6.3 Teva Pharmaceutical Industries Ltd
6.3.1 Teva Pharmaceutical Industries Ltd Company Information
6.3.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolio
6.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Company Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Candida Infections Drugs Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer Inc
6.5.1 Pfizer Inc Company Information
6.5.2 Pfizer Inc Description and Business Overview
6.5.3 Pfizer Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Inc Candida Infections Drugs Product Portfolio
6.5.5 Pfizer Inc Recent Developments/Updates
6.6 GSK plc
6.6.1 GSK plc Company Information
6.6.2 GSK plc Description and Business Overview
6.6.3 GSK plc Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 GSK plc Candida Infections Drugs Product Portfolio
6.6.5 GSK plc Recent Developments/Updates
6.7 Novartis AG
6.7.1 Novartis AG Company Information
6.7.2 Novartis AG Description and Business Overview
6.7.3 Novartis AG Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Novartis AG Candida Infections Drugs Product Portfolio
6.7.5 Novartis AG Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Company Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 AstraZeneca Candida Infections Drugs Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Johnson & Johnson Private Limited
6.9.1 Johnson & Johnson Private Limited Company Information
6.9.2 Johnson & Johnson Private Limited Description and Business Overview
6.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolio
6.9.5 Johnson & Johnson Private Limited Recent Developments/Updates
6.10 Sun Pharmaceutical Industries Ltd
6.10.1 Sun Pharmaceutical Industries Ltd Company Information
6.10.2 Sun Pharmaceutical Industries Ltd Description and Business Overview
6.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolio
6.10.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.11 Merck & Co., Inc
6.11.1 Merck & Co., Inc Company Information
6.11.2 Merck & Co., Inc Description and Business Overview
6.11.3 Merck & Co., Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Merck & Co., Inc Candida Infections Drugs Product Portfolio
6.11.5 Merck & Co., Inc Recent Developments/Updates
6.12 Bristol-Myers Squibb Company
6.12.1 Bristol-Myers Squibb Company Company Information
6.12.2 Bristol-Myers Squibb Company Description and Business Overview
6.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolio
6.12.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.13 Lilly
6.13.1 Lilly Company Information
6.13.2 Lilly Description and Business Overview
6.13.3 Lilly Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Lilly Candida Infections Drugs Product Portfolio
6.13.5 Lilly Recent Developments/Updates
6.14 Amgen Inc
6.14.1 Amgen Inc Company Information
6.14.2 Amgen Inc Description and Business Overview
6.14.3 Amgen Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Amgen Inc Candida Infections Drugs Product Portfolio
6.14.5 Amgen Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Candida Infections Drugs Industry Chain Analysis
7.2 Candida Infections Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Candida Infections Drugs Production Mode & Process Analysis
7.4 Candida Infections Drugs Sales and Marketing
7.4.1 Candida Infections Drugs Sales Channels
7.4.2 Candida Infections Drugs Distributors
7.5 Candida Infections Drugs Customer Analysis
8 Candida Infections Drugs Market Dynamics
8.1 Candida Infections Drugs Industry Trends
8.2 Candida Infections Drugs Market Drivers
8.3 Candida Infections Drugs Market Challenges
8.4 Candida Infections Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK
Novartis
Astrazeneca plc
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd.
Merck& Co. Inc
Bristol Myers Squibb Company
Lilly
Amgen Inc
List of Tables
 Table 1. Global Candida Infections Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Candida Infections Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Candida Infections Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Candida Infections Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Candida Infections Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Candida Infections Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Candida Infections Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Candida Infections Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Candida Infections Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Candida Infections Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Candida Infections Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Candida Infections Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Candida Infections Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Candida Infections Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Candida Infections Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Candida Infections Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Candida Infections Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Candida Infections Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Candida Infections Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Candida Infections Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Candida Infections Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Candida Infections Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Candida Infections Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Candida Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Candida Infections Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Candida Infections Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Candida Infections Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Candida Infections Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Candida Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Candida Infections Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Candida Infections Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Candida Infections Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Candida Infections Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Candida Infections Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Candida Infections Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Candida Infections Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Candida Infections Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Candida Infections Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Candida Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Candida Infections Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Candida Infections Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Candida Infections Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Candida Infections Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Candida Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Candida Infections Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Candida Infections Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Candida Infections Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Candida Infections Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Candida Infections Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Candida Infections Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Candida Infections Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Candida Infections Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Candida Infections Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Candida Infections Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Candida Infections Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Candida Infections Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Candida Infections Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Candida Infections Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Candida Infections Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Candida Infections Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Candida Infections Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Candida Infections Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Candida Infections Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Candida Infections Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Candida Infections Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Candida Infections Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Candida Infections Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Candida Infections Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. F. Hoffmann-La Roche Ltd Company Information
 Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview
 Table 72. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product
 Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates
 Table 75. Mylan NV Company Information
 Table 76. Mylan NV Description and Business Overview
 Table 77. Mylan NV Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Mylan NV Candida Infections Drugs Product
 Table 79. Mylan NV Recent Developments/Updates
 Table 80. Teva Pharmaceutical Industries Ltd Company Information
 Table 81. Teva Pharmaceutical Industries Ltd Description and Business Overview
 Table 82. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product
 Table 84. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
 Table 85. Sanofi Company Information
 Table 86. Sanofi Description and Business Overview
 Table 87. Sanofi Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Sanofi Candida Infections Drugs Product
 Table 89. Sanofi Recent Developments/Updates
 Table 90. Pfizer Inc Company Information
 Table 91. Pfizer Inc Description and Business Overview
 Table 92. Pfizer Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Inc Candida Infections Drugs Product
 Table 94. Pfizer Inc Recent Developments/Updates
 Table 95. GSK plc Company Information
 Table 96. GSK plc Description and Business Overview
 Table 97. GSK plc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. GSK plc Candida Infections Drugs Product
 Table 99. GSK plc Recent Developments/Updates
 Table 100. Novartis AG Company Information
 Table 101. Novartis AG Description and Business Overview
 Table 102. Novartis AG Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Novartis AG Candida Infections Drugs Product
 Table 104. Novartis AG Recent Developments/Updates
 Table 105. AstraZeneca Company Information
 Table 106. AstraZeneca Description and Business Overview
 Table 107. AstraZeneca Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. AstraZeneca Candida Infections Drugs Product
 Table 109. AstraZeneca Recent Developments/Updates
 Table 110. Johnson & Johnson Private Limited Company Information
 Table 111. Johnson & Johnson Private Limited Description and Business Overview
 Table 112. Johnson & Johnson Private Limited Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Johnson & Johnson Private Limited Candida Infections Drugs Product
 Table 114. Johnson & Johnson Private Limited Recent Developments/Updates
 Table 115. Sun Pharmaceutical Industries Ltd Company Information
 Table 116. Sun Pharmaceutical Industries Ltd Description and Business Overview
 Table 117. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product
 Table 119. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
 Table 120. Merck & Co., Inc Company Information
 Table 121. Merck & Co., Inc Description and Business Overview
 Table 122. Merck & Co., Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Merck & Co., Inc Candida Infections Drugs Product
 Table 124. Merck & Co., Inc Recent Developments/Updates
 Table 125. Bristol-Myers Squibb Company Company Information
 Table 126. Bristol-Myers Squibb Company Description and Business Overview
 Table 127. Bristol-Myers Squibb Company Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Bristol-Myers Squibb Company Candida Infections Drugs Product
 Table 129. Bristol-Myers Squibb Company Recent Developments/Updates
 Table 130. Lilly Company Information
 Table 131. Lilly Description and Business Overview
 Table 132. Lilly Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Lilly Candida Infections Drugs Product
 Table 134. Lilly Recent Developments/Updates
 Table 135. Amgen Inc Company Information
 Table 136. Amgen Inc Description and Business Overview
 Table 137. Amgen Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Amgen Inc Candida Infections Drugs Product
 Table 139. Amgen Inc Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Candida Infections Drugs Distributors List
 Table 143. Candida Infections Drugs Customers List
 Table 144. Candida Infections Drugs Market Trends
 Table 145. Candida Infections Drugs Market Drivers
 Table 146. Candida Infections Drugs Market Challenges
 Table 147. Candida Infections Drugs Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Candida Infections Drugs
 Figure 2. Global Candida Infections Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Candida Infections Drugs Market Share by Type: 2024 & 2031
 Figure 4. Azole Product Picture
 Figure 5. Nystatin Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Candida Infections Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Candida Infections Drugs Market Share by Application: 2024 & 2031
 Figure 9. Beriberi
 Figure 10. Jock Itch
 Figure 11. Vaginal Infection
 Figure 12. Other
 Figure 13. Global Candida Infections Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Candida Infections Drugs Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Candida Infections Drugs Sales (2020-2031) & (K Units)
 Figure 16. Global Candida Infections Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 17. Candida Infections Drugs Report Years Considered
 Figure 18. Candida Infections Drugs Sales Share by Manufacturers in 2024
 Figure 19. Global Candida Infections Drugs Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Candida Infections Drugs Players: Market Share by Revenue in Candida Infections Drugs in 2024
 Figure 21. Candida Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Candida Infections Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Candida Infections Drugs Sales Market Share by Country (2020-2031)
 Figure 24. North America Candida Infections Drugs Revenue Market Share by Country (2020-2031)
 Figure 25. United States Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Candida Infections Drugs Sales Market Share by Country (2020-2031)
 Figure 28. Europe Candida Infections Drugs Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Candida Infections Drugs Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Candida Infections Drugs Revenue Market Share by Region (2020-2031)
 Figure 36. China Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Candida Infections Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Candida Infections Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Candida Infections Drugs Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Candida Infections Drugs Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Candida Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Candida Infections Drugs by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Candida Infections Drugs by Type (2020-2031)
 Figure 55. Global Candida Infections Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Candida Infections Drugs by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Candida Infections Drugs by Application (2020-2031)
 Figure 58. Global Candida Infections Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 59. Candida Infections Drugs Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Candida Infection Testing Market Research Report 2025
Vaginal Fungi Infections Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Systemic Candidiasis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Invasive Candidiasis Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Fluconazole Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Vaginal Fungal Infections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Vulvovaginal Candidiasis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diagnosing Fungal Infections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Enterobacteriaceae Infection Drug Market Research Report 2024
Human Papillomavirus Infection Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hospital Acquired Infections Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Candidiasis Therapeutics Market Research Report 2024
Invasive Fungal Infection Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti fungal Drugs Market Insights Forecast to 2030
Global Anti invasive Fungal Infection IFI Drug Market Research Report 2024
Fungal Nail Infections Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Staphylococcal Infection Drugs Market Insights Forecast to 2030
Global Eye Infection Drugs Market Insights Forecast to 2030
OTC Topical Antifungals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Yeast Culture Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions